Ionis Enters $500m+ Agreement With Royalty Pharma To Help Fund Late-Stage Pipeline
Including Wholly Owned Assets
The US firm has sold some of its royalty stream for the gene therapy Spinraza and cardiovascular drug candidate, pelacarsen, to Royalty Pharma for $500m upfront, which should help fund upcoming milestones for Ionis’ late-stage pipeline.
